DDInter1628 DDInter1882
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
A macrolide antibiotic that is similar to erythromycin.
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Amoxicillin
Amoxicillin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Ixabepilone
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Loratadine
Loratadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Irinotecan
Irinotecan {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ixabepilone
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Vinorelbine
Vinorelbine {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Ruxolitinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amoxicillin (Compound) and Amoxicillin may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ruxolitinib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Ixabepilone (Compound) and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loratadine (Compound) and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ruxolitinib (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Irinotecan (Compound) and Irinotecan may lead to a major life threatening interaction when taken with Troleandomycin
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Fexofenadine (Compound) and Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound) and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Vinorelbine (Compound) and Vinorelbine may lead to a major life threatening interaction when taken with Troleandomycin